Clinical Trials Logo

JIA clinical trials

View clinical trials related to JIA.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06284616 Completed - Clinical trials for Patient Satisfaction

JASP-1 for Children Recently Diagnosed and Their Parents

JASP-1
Start date: August 15, 2019
Phase: N/A
Study type: Interventional

To implement and evaluate a patient-and family-centered Juvenile Arthritis Support Program during one year (JASP-1) for children recently diagnosed with JIA and their parents and after 12 months compare satistaction with care and health outcomes with a control group receiving standard care.

NCT ID: NCT05603286 Completed - JIA Clinical Trials

Using Self-evaluation to Increase Visit Intervals in Juvenile Idiopathic Arthritis

THUIS
Start date: March 28, 2022
Phase: N/A
Study type: Interventional

In the THUIS study, JIA patients in clinical remission will skip one 3-monthly hospital control visit and instead monitor their disease activity at home. Outcomes at 6 months will be compared to those from a historical cohort.

NCT ID: NCT04168034 Completed - JIA Clinical Trials

iParent2Parent Program for Parents of Children With Juvenile Idiopathic Arthritis

iPa2PaJIA
Start date: August 15, 2019
Phase: N/A
Study type: Interventional

The iParent2Parent program matches parents of children living with arthritis with a trained parent mentor who will provide parents of children newly diagnosed with arthritis: practical coping advice and social support through shared lived experiences. This study will compare two groups of parents: those who are in the iParent2Parent program and those in the control group (no mentor).

NCT ID: NCT00783510 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis (JIA) Registry

STRIVE
Start date: July 11, 2008
Phase:
Study type: Observational

This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.